Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 143-147 , September 2009

Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab

References 

  1. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–546
  2. De Boeck K. Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Monaldi Arch Chest Dis. 1996;51:210–213
  3. Murphy B, Phelan PD, Jack I, et al. Seasonal pattern in childhood viral lower respiratory tract infections. Med J Aust. 1980;1:22–24
  4. Fitzgerald DA, Kilham HA, Bronchiolitis: . Assessment and evidence based management. Med J Aust. 2004;180:399–404
  5. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003;22:S46–54
  6. Lanari M, Giovannini M, Giuffre L, et al. Investigators RADAR Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol. 2002;33:458–465
  7. Institute of Medicine [1998]. Institute of Medicine Committee on Issues and Priorities for new vaccine development; prospects fro immunizing against respiratory syncytial virus, In: New vaccine Development, Establishing Priorities, Washington DC: National Academy of Science Press; 1998: 1: 397-409.
  8. Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865–870
  9. Cunningham CK, Macmillan JA, Gross SJ. Rehospitalisation for respiratory illness in infants of less than 32 weeks gestation. Pediatrics. 1991;88:527–532
  10. Yuksel B, Greenough A. Birthweight and hospital readmission in infants born prematurely. Arch Pediatr Adolesc Med. 1994;148:384–388
  11. American Academy of Pediatrics: Committee on Infectious Disease and Committee on fetus and Newborn Prevention of respiratory Syncytial Virus Infection. Indication for the use of palivizumab and follow-up data on the use of RSV-IG. Pediatrics 1998; 102: 1211-1216.
  12. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540
  13. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of Palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatr 2004; 112: 1442-1446.
  14. Reeve CA, Whitehall JS, Buettner PG, et al. Predicting respiratory syncytial virus hospitalization in Australian children. J Paediatr Child Health. 2006;42:248–252
  15. Grimaldi M, Gouyon B, Sagot P, et al. Burgundy Perinatal Network. Palivizumab efficacy in preterm infants with gestational age < or equal 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol. 2007;42:189–192
  16. Navas L, Wang E, deCarvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992;121:348–354
  17. Purcell K, Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991to 2002. Pediatr Infect Dis J. 2004;23:418–423
  18. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory virus in the United States. JAMA. 2003;289:170–186
  19. Fleming DM, Pannell RS, Cross KW. Mortality from influenza and respiratory syncytial virus. J Epidemiol Community Health. 2005;59:589–590
  20. Infectious Diseases and Immunization Committee, Canadian Paediatric Society, Respiratory syncytial virus immune globulin intravenous. Pediatr Child Health 1998; 3: 11-14.
  21. Posfay-Barbe KM, Zerr DM, Pittet D. Infection control in paediatrics. Lancet. 2008;8:19–30
  22. Simoes EA, Sondheimer HM, Top FH, et al. The Cardiac Study Group Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus in infants and children with congenital heart disease. J Pediatr. 1998;133:492–499
  23. Groothius JR, Simoes EA, Levin MJ. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Eng J Med. 1993;329:1524–1530
  24. Simoes EA, Groothius JR. Respiratory syncytial virus prophylaxis—the story so far. Respir Med. 2002;96(Suppl B):S15–S24Review
  25. Carbonell-Estrany X, Giuffre L, Kimpen JLL, et al. Guidelines for the use of Synagis [palivizumab], a humanized monoclonal antibody, for the prevention of respiratory syncytial virus [RSV] disease in high-risk infants: A consensus opinion. Infect Med. 1999;16:29–33
  26. Meissner HC, Groothius JR, Rodriguez WJ, et al. Safety and pharmacokinetics of an intramuscular monoclonal antibody [SB 209763] against respiratory syncytial virus [RSV] in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother. 1999;43:1183–1188
  27. IMpact-RSV Study Group. Palivizumab, a humanized respiratory virus monoclonal antibody, reduced hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531-537.
  28. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody [MEDI-493] with potent in vitro and in vivo activity against Respiratory Syncytial Virus. J Infect Dis. 1997;176:1215–1224
  29. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:110–115
  30. Saez-Lorens X, Castano E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:787–791
  31. Fenton C, Scott LJ, Plosker GL, Palivizumab: . A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection. Pediatr Drugs. 2004;6:177–197
  32. Lanari M, Rossi GA, Merolla R, et al. High risk of nosocomial-acquired RSV infection in children with congenital heart disease. J Pediatr. 2004;145:140
  33. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory Syncytial Virus Bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507
  34. Sigurs N, Gustafsson P, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171: 137-141.
  35. Pullan CR, Hey EN. Wheezing, asthma and pulmonary dysfunction 10 years after infection with respiratory syncytial virus. BMJ. 1982;284:1665–1669
  36. Stein RT, Sherril D, Morgan WJ, et al. Respiratory Syncytial Virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541–545
  37. Korppi M, Piippo-Savolainen E, Korhonen K, et al. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004;38:155–160
  38. Robertson CF, Roberts MF, Kappers JH. Asthma prevalence in Melbourne schoolchildren: have we reached the peak?. Med J Aust. 2004;180:273–276
  39. Naver L, Eriksson M, Ewald U, et al. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Acta Paediatr. 2004;93:1470–1473
  40. Tulloh RM, Feltes TF. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital heart disease. Cardiol Young. 2005;15:274–278Review
  41. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health. 2000;36:422–427
  42. Vogel AM, Lennon DR, Broadbent R, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high risk infants. J Paediatr Child Health. 2002;38:550–554
  43. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high risk children: A UK analysis. Pharmacoeconomics. 2007;25:55–71
  44. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects-hospitalizations and costs. Acta Paediatr. 2006;95:404–406
  45. http://www.copdx.org.au/guidelines/a_ref_1.asp#ref5.

PII: S1526-0542(09)00044-X

doi: 10.1016/j.prrv.2009.06.002

Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 143-147 , September 2009

Article Tools